Alzamend Neuro (NASDAQ:ALZN) Director Milton Ault III Sells 43,238 Shares

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 43,238 shares of the stock in a transaction on Tuesday, September 23rd. The stock was sold at an average price of $2.38, for a total transaction of $102,906.44. Following the completion of the sale, the director owned 65,022 shares in the company, valued at $154,752.36. The trade was a 39.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Alzamend Neuro Stock Performance

NASDAQ ALZN opened at $2.36 on Friday. Alzamend Neuro, Inc. has a 1 year low of $2.06 and a 1 year high of $17.10. The company has a fifty day moving average of $2.48 and a 200 day moving average of $4.29.

Analysts Set New Price Targets

A number of brokerages have issued reports on ALZN. Ascendiant Capital Markets decreased their price target on Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday. Wall Street Zen lowered shares of Alzamend Neuro from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $42.00.

Institutional Trading of Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC bought a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro at the end of the most recent reporting period. Institutional investors and hedge funds own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.